Viela Bio, a late-stage biotech developing therapies for autoimmune diseases, filed on Thursday with the SEC to raise up to $150 million in an initial public offering.
The Gaithersburg, MD-based company was founded in 2017 and booked $20 million in license revenue for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol VIE. Viela Bio filed confidentially on June 17, 2019. Goldman Sachs, Morgan Stanley, and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Autoimmune biotech Viela Bio files for a $150 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.